# THE EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTHCARE (EDQM)



European Directorate | Direction européenne for the Quality of Medicines | de la qualité du médicament & HealthCare | & soins de santé

#### COUNCIL OF EUROPE



CONSEIL DE L'EUROPE

# **CombiStats online Training module 4**

# Part 1: single-dose assays

# Part 2: combination of assay results



2 © EDQM, Council of Europe, 2025. All rights reserved.

# Content

- Data entry
- Statistical analysis
- Examples
- Dose selection



# **Data entry – quantitative data**

### E.g. immunogenicity test in mice

#### Preparations

		Information	Potency		Pre-d	lilution
Table	Preparation	ID	Potency	Value	Diluted	Injected
1	Standard 🗸	Reference	Assigned	1 unit/dose	1 dose/2 ml	0.5 ml/mouse
2	Sample 1 🝷	Batch	Assumed -	1 unit/dose	1 dose/ml	0.5 ml/mouse

Table 1			Table 2	
Preparation	Standard		Preparation	Sample 1
ID	Reference		ID	Batch
Potency	Assigned		Potency	Assumed
Potency value	1 unit/dose		Potency value	1 unit/dos
Diluted	1 dose/2 ml		Diluted	1 dose/ml
Injected	0.5 ml/mouse		Injected	0.5 ml/mo
Dose	1/1		Dose	1/1
Rep.1	0.867		Rep.1	1.068
Rep.2	0.568		Rep.2	0.845
Rep.3	0.674		Rep.3	0.964
Rep.4	0.550		Rep.4	1.274
Rep.5	0.598		Rep.5	0.686
Rep.6	0.732		Rep.6	1.160

abl	e 2
	Sample 1
	Batch
	Assumed
ue	1 unit/dose
	1 dose/ml
	0.5 ml/mouse
	1/1
	1.068
	0.845
	0.964

#### or

#### Raw data

Table 1			
Preparation	Standard		
ID	Reference		
Potency	Assigned		
Potency value	1 unit/dose		
Diluted	1 dose/2 ml		
Injected	0.5 ml/mouse		
Dose	1/1 1/1		
Rep.1	0.867	0.550	
Rep.2	0.568	0.598	
Rep.3	0.674 0.732		

•	Table 2			
Preparation	paration Sample 1			
ID	Batch			
Potency	Assumed			
Potency value 1 unit/dose				
Diluted	Diluted 1 dose/ml			
Injected	0.5 ml/	mouse		
Dose	1/1	1/1	1/1	
Rep.1	1.068	1.274	0.964	
Rep.2	0.845	0.686	1.160	

# Unique dose repeated in different columns (or rows)



# **Data entry – quantal data**

#### E.g. in vivo test

#### Preparations

		Information	Pote	ncy
Table	Preparation	ID	Potency	Value
1	Standard 🗸	Reference	Assigned	8 IU/ml
2	Sample 1 🝷	Potent lot	Assumed -	2.5 IU/ml
3	Sample 2 🗸	Sub-potent lot	Assumed +	2.5 IU/ml

# Aggregated data (r/n)

#### Raw data

Table 1		
Preparation	Standard	
ID	Reference	
Potency	Assigned	
Potency value	8 IU/ml	
Dose	Rep.1	
1/300	20/28	

Table	2 :
Preparation	Sample 1
ID	Potent lot
Potency	Assumed
Potency value	2.5 IU/ml
Dose	Rep.1
1/30	10/28

Table 3		
Preparation	Sample 2	
ID	Sub-potent lot	
Potency	Assumed	
Potency value	2.5 IU/ml	
Dose	Rep.1	
1/30	15/28	

Individual data

Table 1				
Preparation	Standard			
ID	Refere	Reference		
Potency	Assign	ed		
Potency value	8 IU/m	8 IU/ml		
Dose	1/300	1/300		
Rep.1	1	1		
Rep.2	1	0		
Rep.3	1	1		
Rep.4	0	1		
Rep.5	1	0		
Rep.6	1	1		
Rep.7	1	1		
Rep.8	0	0		
Rep.9	0	1		
Rep.10	1	1		
Rep.11	1	1		
Rep.12	0	1		
Rep.13	1	1		
Rep.14	1	0		
r/n	10/14	10/14		

Tabl	Table 2		
Preparation	Sample 1		
D	Potent lot		
Potency	Assum	ed	
Potency value	2.5 IU/ml		
Dose	1/30	1/30	
Rep.1	1	0	
Rep.2	0	1	
Rep.3	1	0	
Rep.4	0	0	
Rep.5	0	1	
Rep.6	1	0	
Rep.7	0	0	
Rep.8	0	0	
Rep.9	0	0	
Rep.10	0	1	
Rep.11	1	0	
Rep.12	1	0	
Rep.13	0	1	
Rep.14	1	0	
r/n	6/14	4/14	

Tab	Table 3			
Preparation	Sample 2			
ID	Sub-po	Sub-potent lot		
Potency	Assume	ed		
Potency value	2.5 IU/r	2.5 IU/ml		
Dose	1/30	1/30		
Rep.1	0	1		
Rep.2	1	0		
Rep.3	1	1		
Rep.4	0	0		
Rep.5	1	1		
Rep.6	0	0		
Rep.7	1	1		
Rep.8	1	1		
Rep.9	1	0		
Rep.10	0	0		
Rep.11	0	1		
Rep.12	1	1		
Rep.13	1	0		
Rep.14	0	0		
r/n	8/14	7/14		



# "Show design" option

### **Quantitative data**

#### Assay layout

Design	c1	<b>c2</b>	c3	Observ.	1.	<b>c1</b>
r1	1 1 1	2 1 5	1 1 5	r1		0.867
r2	2 1 3	1 1 3	1 1 2	r2	0	.964
r3	2 1 6	2 1 1	2 1 4	r3	1.1	160
r4	2 1 2	1 1 4	1 1 6	r4	0.8	45

#### **Blank results**

0.002 0.007 0.005 0.004 0.007	Mean	30	RSD%
	0.005	0.002	121

#### Quantal data (e.g. individual data)

#### Assay layout

Design	<b>c1</b>	c2	<b>c3</b>	<b>c4</b>	<b>c5</b>	сб
r1	1 1 1	2 1 1	3 1 1	1 1 15	2 1 15	3 1 15
r2	1 1 2	2 1 2	3 1 2	1 1 16	2 1 16	3 1 16
r3	1 1 3	2 1 3	3 1 3	1 1 17	2 1 17	3 1 17
r4	1 1 4	2 1 4	3 1 4	1 1 18	2 1 18	3 1 18
r5	1 1 5	2 1 5	3 1 5	1 1 19	2 1 19	3 1 19
r6	1 1 6	2 1 6	3 1 6	1 1 20	2 1 20	3 1 20
r7	1 1 7	2 1 7	3 1 7	1 1 21	2 1 21	3 1 21
r8	1 1 8	2 1 8	3 1 8	1 1 22	2 1 22	3 1 22
r9	1 1 9	2 1 9	3 1 9	1 1 23	2 1 23	3 1 23
r10	1 1 10	2 1 10	3 1 10	1 1 24	2 1 24	3 1 24
r11	1 1 11	2 1 11	3 1 11	1 1 25	2 1 25	3 1 25
r12	1 1 12	2 1 12	3 1 12	1 1 26	2 1 26	3 1 26
r13	1 1 13	2 1 13	3 1 13	1 1 27	2 1 27	3 1 27
r14	1 1 14	2 1 14	3 1 14	1 1 28	2 1 28	3 1 28

Observ.	<b>c1</b>	c2	c3	<b>c4</b>	c5	сб
r1	1	1	0	1	0	1
r2	1	0	1	0	1	0
r3	1	1	1	1	0	1
r4	0	0	0	1	0	0
r5	1	0	1	0	1	1
r6	1	1	0	1	0	0
r7	1	0	1	1	0	1
r8	0	0	1	0	0	1
r9	0	0	1	1	0	0
r10	1	0	0	1	1	0
r11	1	1	0	1	0	1
r12	0	1	1	1	0	1
r13	1	0	1	1	1	0
r14	1	1	0	0	0	0




# Content

- Data entry
- Statistical analysis
- Examples
- Dose selection



# **Descriptive plot**

Quantitative data



#### Europen Directorie Il Directorie empiricatione forthe Bubly led qualité of Medicines ja medicament 8 Hardhacia Issande sande

8 © EDQM, Council of Europe, 2025. All rights reserved.

# **Statistical test** – quantitative data

A test comparing the location of the data of the preparations

Location = means → t-test (2 preps), multiple comparisons test (> 2 preps)

Assumption: data should be normally distributed (Gauss distributions)

May not be the case for some bioassays...

E.g. immunogenicity test in mice (antibody units) – normal distributions?

CombiStats approach: a test applicable to any distribution (distribution-free statistics); data from a completely randomised design

→ Wilcoxon-Mann-Whitney test

Table	1 :
Preparation	Standard
ID	S
Potency	Assigned
Potency value	1 IU/dose
Dose	1 dose
Rep.1	4.4
Rep.2	12.2
Rep.3	8.5
Rep.4	8.5
Rep.5	1.8
Rep.6	7.2
Rep.7	7.2
Rep.8	8.5
Rep.9	3.1
Rep.10	10.2

<b>–</b> 1	able 2	2 :
Preparati	on	Sample 1
ID		Т
Potency		Assumed
Potency	/alue	? IU/dose
Dose		1 dose
Rep.1	1	10.2
Rep.2	2	16.9
Rep.3	3	11.7
Rep.4	4	10.2
Rep.5	5	10.2
Rep.6	5	10.2
Rep.7	7	8.5
Rep.8	3	0.1
Rep.9	9	0.1
Rep.1	0	8.5



Compares the distributions of results from two preparations

0.5 ml/mouse 1/1

**Principle:** the values, listed in ascending order, will alternate between the 2 preparations if their underlying distributions are equal

Tabl	e1 :	E Ta	ble 2
Preparation	Standard	Preparation	Sample 1
ID	Reference	ID	Batch
Potency	Assigned	Potency	Assumed
Potency value	1 unit/dose	Potency valu	e 1 unit/dose
Diluted	1 dose/2 ml	Diluted	1 dose/ml
Injected	0.5 ml/mouse	Injected	0.5 ml/mous
Dose	1/1	Dose	1/1
Rep.1	0.867	Rep.1	1.068
Rep.2	0.568	Rep.2	0.845
Rep.3	0.674	Rep.3	0.964
Rep.4	0.550	Rep.4	1.274
Rep.5	0.598	Rep.5	0.686
Rep.6	0.732	Rep.6	1.160

Data in ascending order. Do they alternate between the 2 prep?	•
Not really (have a look at the descriptive plot too)	

Obse	v. c1	c2	<b>c</b> 3	<b>c4</b>	c5	с6	c7	<b>c</b> 8	c9	c10	c11	c12
r1	0.550	0.568	0.598	0.674	0.686	0.732	0.845	0.867	0.964	1.068	1.160	1.274

Rank	9
approach	(rai

Std data in position Sample data in position ank) 1, 2, 3, 4, 6 and 8 (rank) 5, 7, 9, 10, 11 and 12

#### Limit test

		Limit tested				
Preparation	Units	Value	Probability	Level of significance		
Sample 1: Batch	unit/dose	0.5	0.007576	**		

p-value  $\leq 0.05$  (usual significance threshold)  $\rightarrow$  the 2 distributions of results differ significantly



### Is useful in a case of skewed data: the **rank approach** relaxes the effects of extreme values

Table	1 :	Table	2
Preparation	Standard	Preparation	Sample 1
ID	S	ID	т
Potency	Assigned	Potency	Assigned
Potency value	160 IU/vial	Potency value	80 IU/dose
Dose	1 IU	Dose	2.5 IU
Rep.1	0	Rep.1	0.042
Rep.2	0	Rep.2	0.8
Rep.3		Rep.3	0.1
Rep.4	0.1	Rep.4	0.283
Rep.5	0.2	Rep.5	0.141
Rep.6	0	Rep.6	0.238
Rep.7		Rep.7	0.283
Rep.8	0.168	Rep.8	0.168
Rep.9	0.084	Rep.9	0
Rep.10	0.059	Rep.10	0
Rep.11	0	Rep.11	0.168
Rep.12	0	Rep.12	0.084

Vero cell assay: values < LOD set to 0

Has many advantages over parametric methods (e.g. t-test)

- No assumptions on normality nor homoscedasticity have to be made
- Applicable to various types of responses:
  - Quantal data (yes/no, e.g. lethal challenge)
  - Scores (e.g. intradermal challenge)
  - Quantitative data (e.g. ELISA absorbances)
  - Mixed data (e.g. quantitative data with a category "below detection limit")
- Not sensitive to outliers
- No transformation of responses is necessary
- In many practical cases, it is statistically more efficient than the t-test

# However, for a single-dose assay to be valid, the condition of similarity of dose-response curves must be fulfilled



# **Limit tested**


#### Limit test

		Limit tested			
Preparation	Units	Value Probability Level of significa			
Sample 1: Batch	unit/dose	0.5	0.007576	**	

### p-value ≤ 0.05 (usual significance threshold) → the 2 distributions of results differ significantly

Tabl	le 1	Tabl	le 2 :
Preparation	Standard	Preparation	Sample 1
ID	Reference	ID	Batch
Potency	Assigned	Potency	Assumed
Potency value	1 unit/dose	Potency value	1 unit/dose
Diluted	1 dose/2 ml	Diluted	1 dose/ml
Injected	0.5 ml/mouse	Injected	0.5 ml/mouse
Dose	1/1	Dose	1/1

More precisely, **Sample 1 has a potency** significantly higher than 0.5 unit/dose



See the note for guidance, page 5 for further examples



# Content

- Data entry
- Statistical analysis
- Examples
- Dose selection



# **Example 1**


#### **Multiple-dose assay**

The signal increases with the dose (positive slope)

	Table 1		
Preparation	Standa	rd	
ID	S		
Potency	Assigne	ed	
Potency value	5000 IU/mg		
Dose	1/45	1/30	1/20
Rep.1	161	171	187
Rep.2	150	172	192
Rep.3	161	174	195
Rep.4	163	184	194
Rep.5	151	176	201
Rep.6	166	182	198

Table 4

•	:		
Preparation	Sample	e 1	
ID	Т		
Potency	Assum	ed	
Potency value	5600 IL	J/mg	
Dose	1/45	1/30	1/20
Rep.1	170	188	204
Rep.2	161	180	202
Rep.3	161	172	203
Rep.4	170	181	209
Rep.5	164	191	212
Rep.6	171	196	203
•			



### Single-dose assay

#### positive slope



Table 1					
Preparation	eparation Standard				
ID	S				
Potency	Assigne	ed			
Potency value	e 5000 IU/mg				
Dose	1/45	1/30	1/20		
Rep.1	<del>161</del>	<del>171</del>	187		
Rep.2	<del>150</del>	<del>172</del>	192		
Rep.3	<del>161</del>	<del>174</del>	195		
Rep.4	<del>163</del>	<del>184</del>	194		
Rep.5	<del>151</del>	<del>176</del>	201		
Rep.6	<del>166</del>	<del>182</del>	198		

•	Table 2				
Preparation	Sample	e 1			
ID	Т				
Potency	Assumed				
Potency value	e 5600 IU/mg				
Dose	1/45	1/30	1/20		
Rep.1	<del>170</del>	<del>188</del>	204		
Rep.2	<del>161</del>	<del>180</del>	202		
Rep.3	<del>161</del>	<del>172</del>	203		
Rep.4	<del>170</del>	<del>181</del>	209		
Rep.5	<del>164</del>	<del>191</del>	212		
Rep.6	<del>171</del>	<del>196</del>	203		

# The potency of Sample 1 is significantly **higher** (p=0.001) than 5000 IU/mg

#### Limit test

		Limit tested				
Preparation	Units	Value	Probability	Level of significance		
Sample 1: T	IU/mg	5000	0.001082	**		



# **Example 2**


#### Multiple-dose assay

The signal decreases with the dose (negative slope)

-	lable I		ě.
Preparation	Standa	rd	
ID	S		
Potency	Assigne	ed	
Potency value	5000 IL	J/mg	
Dose	1/20	1/30	1/45
Rep.1	161	171	187
Rep.2	150	172	192
Rep.3	161	174	195
Rep.4	163	184	194
Rep.5	151	176	201
Rep.6	166	182	198

Table 1

-	Table 2		:
Preparation	Sample	e 1	
ID	Т		
Potency	Assum	ed	
Potency value	5600 IU/mg		
Dose	1/20	1/30	1/45
Rep.1	170	188	204
Rep.2	161	180	202
Rep.3	161	172	203
Rep.4	170	181	209
Rep.5	164	191	212
Rep.6	171	196	203



### Single-dose assay

#### negative slope



•	Table 1					
Preparation	Standa	rd				
ID	S					
Potency	Assigne	ed				
Potency value	5000 IU/mg					
Dose	1/20	1/30	1/45			
Rep.1	<del>161</del>	<del>171</del>	187			
Rep.2	<del>150</del>	<del>172</del>	192			
Rep.3	<del>161</del> <del>174</del> 195		195			
Rep.4	<del>163</del>	<del>184</del>	194			
Rep.5	<del>151</del>	<del>176</del>	201			
Rep.6	<del>166</del>	<del>182</del>	198			

• ·	Table 2			
Preparation	Sample	e 1		
ID	Т			
Potency	Assum	ed		
Potency value	5600 IU/mg			
Dose	1/20	1/30	1/45	
Rep.1	<del>170</del>	<del>188</del>	204	
Rep.2	<del>161</del>	<del>180</del>	202	
Rep.3	<del>161</del>	<del>172</del>	203	
Rep.4	<del>170</del>	<del>181</del>	209	
Rep.5	<del>164</del>	<del>191</del>	212	
Rep.6	<del>171</del>	<del>196</del>	203	

# The potency of Sample 1 is significantly **lower** (p=0.001) than 5000 IU/mg

#### Limit test

		Limit tested				
Preparation	Units	Value	Probability	Level of significance		
Sample 1: T	IU/mg	5000	0.001082	**		



# **Limit test interpretation**

### It is only possible to determine if the potency of the test preparation is lower or higher than the limit value if the signal-dose relationship is known

	Signal-dose relationship			
Response of the test preparation	Results decrease when dose increases ( <b>negative slope</b> )	Results increase with the dose ( <b>positive slope</b> )		
<b>Lower</b> than that of the standard	The potency of the test preparation is significantly higher than the limit value	The potency of the test preparation is significantly lower than the limit value		
<b>Greater</b> than that of the standard	The potency of the test preparation is significantly lower than the limit value	The potency of the test preparation is significantly higher than the limit value		

E.g. Immunodiffusion test:

Limit value = 16700 IU/vial (p-value  $\leq$  0.001)

Results of the test preparation are higher than those of the standard.

→ The test preparation contains significantly [more]/[less] (please choose) than 16700 IU/vial



# **Example 3**

### The Wilcoxon-Mann-Whitney test also applies to quantal data

(the test corresponds to the Fisher's Exact test)

Table	1 :	Table	2
Preparation	Standard	Preparation	Sample 1
ID	Reference	ID	Potent lot
Potency	Assigned	Potency	Assumed
Potency value	8 IU/ml	Potency value	2.5 IU/ml
Dose	1/300	Dose	1/30
Rep.1	20/28	Rep.1	10/28

Tab	le 3
Preparation	Sample 2
ID	Sub-potent lot
Potency	Assumed
Potency value	2.5 IU/ml
Dose	1/30
Rep.1	15/28

#### Limit test

		Limit tested		
Preparation	Units	Value	Probability	Level of significance
Sample 1: Potent lot	IU/ml	0.8	0.007562	**
Sample 2: Sub-potent lot	IU/ml	0.8	0.134734	non-significant

#### 0.70 0.65 -0.60 لة 0.55 أ 0.50 0.45 0.40 0.35 Standard: Reference Sample 1: Potent lot Sample 2: Sub-potent lot Standard Potent lot Sub-potent lot

#### COUNCIL OF FUR edom uropean Directorate | Direction europé for the Quality de la qualité of Medicines du médicament & HealthCare & soins de sant CONSEIL

#### © EDQM, Council of Europe, 2025. All rights reserved. 17


For which interpretation?

# **Example 4**

### The calculation time of the **exact p-value** increases significantly with the number of data

Tab	Table 1			
Preparation	Standa	rd	Prepar	
ID	S		ID	
Potency	Assigne	ed	Potenc	
Potency value	1 IU/do	se	Potenc	
Dose	1 dose	1 dose	Do	
Rep.1	10.1	4.4	Re	
Rep.2	8.5	12.2	Re	
Rep.3	5.0	8.5	Re	
Rep.4	6.0	8.5	Re	
Rep.5	7.1	1.8	Re	
Rep.6	14.3	7.2	Re	
Rep.7	1.3	7.2	Re	
Rep.8	8.5	8.5	Re	
Rep.9	8.5	3.1	Re	
Rep.10	14.3	10.2	Rej	

Table 2				
eparation	Sample 1			
	Т			
tency	Assume	ed		
tency value	? IU/do	se		
Dose	1 dose 1 dose			
Rep.1	0.1	10.2		
Rep.2	17.0	16.9		
Rep.3	12.0	11.7		
Rep.4	10.1 10.2			
Rep.5	3.0 10.2			
Rep.6	24.0	10.2		
Rep.7	20.2	8.4		
Rep.8	14.3	0.1		
Rep.9	8.5	0.1		
Rep.10	12.0	8.4		



# An approximated p-value based on the normal approximation with correction for ties is reported

Limit test

		Limit tested			
Preparation	Units	Value Probability Level of significance			
Sample 1: T	IU/dose	1	0.043519	*	

#### Exact p-value = 0.043



# Example 5 (1)

### From multiple-dose assay...

#### Lethal challenge (n=48 mice/lot)

Table 1		
Preparation	Standard	
ID	S	
Potency	Assigned	
Potency value	160 IU/vial	
Dose	Rep.1	
15.625 IU	11/11	
6.25 IU	12/12	
2.5 IU	8/12	
1 IU	4/10	

Potency estimates

Ph. Eur.

Table	2 :
Preparation	Sample 1
ID	Т
Potency	Assigned
Potency value	80 IU/dose
Dose	Rep.1
15.625 IU	12/12
6.25 IU	11/12
2.5 IU	9/11
1 IU	5/12

Potency

(LCL, UCL)

### to

Potency estimate & UCL not strictly needed and come at a high cost (48 mice/lot)

Is a single dose assay a better option?

### single-dose assay...

Table	1 :
Preparation	Standard
ID	S
Potency	Assigned
Potency value	160 IU/vial
Dose	Rep.1
15.625 IU	<del>11/11</del>
6.25 IU	<del>12/12</del>
2.5 IU	<del>8/12</del>
1 IU	4/10

Table	2
Preparation	Sample 1
ID	Т
Potency	Assigned
Potency value	80 IU/dose
Dose	Rep.1
15.625 IU	<del>12/12</del>
6.25 IU	<del>11/12</del>
2.5 IU	9/11
1 IU	<del>5/12</del>

Limit test

		Limit tested		
Preparation	Units	Value Probability Level of significance		
Sample 1: T	IU/dose	32	0.063467	non-significant

If the lethal challenge assay was restricted to one dose, more than 12 mice/lot would be needed, but not as much as 48...



monograph ≥ <b>32 IU/dose</b> is require	ed
--	----

Sample 1: T IU/dose 85.6132 (41.3355, 175.150)

A lower confidence limit

Preparation Units Estimate

# Example 5 (2)

Expected rates: Standard 1 IU: 40% ; Vaccine lot 2.5 IU: 75%

Let's run the single-dose assay with n = 24 mice/lot

	Std	Lot
n=24	π = 40%	π = 75%
r	P(R = r)	P(R≤r)
5	3%	0%
6	6%	0%
7	10%	0%
8	14%	0%
9	16%	0%
10	16%	0%
11	14%	0%
12	10%	1%
13	6%	1%
14	3%	3%
15	1%	7%
16	1%	11%
17	0%	16%
18	0%	19%
19	0%	18%
20	0%	13%
21	0%	8%
22	0%	3%

The most probable observed rates (Binomial dist.) are: Standard: 10/24 (42%) and Vaccine lot: 18/24 (75%)

		Limit tested			
Preparation	Units	Value	Probability	Level of significance	
Sample 1: T	IU/dose	32	0.019605	*	

#### 40 rates with a higher probabilities of occurrence

1	10/24	18/24	9	11/24	19/24	17	9/24	16/24	25	8/24	16/24	33	7/24	16/24
2	9/24	18/24	10	8/24	19/24	18	11/24	20/24	26	7/24	17/24	34	10/24	15/24
3	10/24	19/24	11	11/24	17/24	19	8/24	20/24	27	12/24	20/24	35	9/24	15/24
4	9/24	19/24	12	8/24	17/24	20	7/24	18/24	28	7/24	20/24	36	13/24	19/24
5	10/24	17/24	13	10/24	20/24	21	12/24	19/24	29	10/24	21/24	37	6/24	18/24
6	9/24	17/24	14	9/24	20/24	22	7/24	19/24	30	9/24	21/24	38	11/24	21/24
7	11/24	18/24	15	12/24	18/24	23	12/24	17/24	31	13/24	18/24	39	8/24	21/24
8	8/24	18/24	16	10/24	16/24	24	11/24	16/24	32	12/24	16/24	40	6/24	19/24

### Proba. of occurrence (10/24: 18/24 as ref.)

<b>`</b>	- 1	/ =/		- /	
	-	0.80	0.61	0.51	0.36
	1.00	0.80	0.60	0.51	0.36
	0.95	0.73	0.60	0.44	0.36
	0.95	0.72	0.60	0.42	0.36
	0.86	0.71	0.58	0.41	0.35
	0.86	0.71	0.56	0.41	0.34
	0.85	0.61	0.53	0.38	0.34
	0.84	0.61	0.52	0.37	0.33

# p-values are $\leq$ 0.05 in 30/40 (75%) cases, $\leq$ 0.10 in 35/40 (88%) cases

o-va	lues

0.020	0.018	0.041	0.021	0.010
0.009	0.002	0.007	0.004	0.124
0.009	0.071	0.001	0.015	0.074
0.004	0.010	0.002	0.000	0.062
0.040	0.003	0.034	0.001	0.001
0.021	0.001	0.001	0.000	0.002
0.038	0.068	0.119	0.114	0.000
0.004	0.073	0.122	0.190	0.000



# Content

- Data entry
- Statistical analysis
- Examples
- Dose selection



# **Dose selection**, limit test


### **1.** Official requirements determine the best ratio between doses

"A lower confidence limit  $\geq$  32 IU/dose is required"

#### Preparations

		Information	Pote	ency
Table	Preparation	ID	Potency	Value
1	Standard 👻	S	Assigned	160 IU/vial
2	Sample 1 👻	Т	Assigned 🗸	80 IU/dose

Assigned potency = 80 IU/doseRatio = 80/32 = 2.5



### **2.** Experience determines the best absolute doses



# **Dose selection**, limit test


### **1.** Official requirements determine the best ratio between doses

"A lower confidence limit  $\geq$  32 IU/dose is required"

#### Preparations

		Information	Pote	ency
Table	Preparation	ID	Potency	Value
1	Standard 👻	S	Assigned	160 IU/vial
2	Sample 1 👻	Т	Assigned 🗸	80 IU/dose

Assigned potency = 80 IU/doseRatio = 80/32 = 2.5



### **2.** Experience determines the best absolute doses



# Part 1: single-dose assay<br/> Part 2: combination of results



24 © EDQM, Council of Europe, 2025. All rights reserved.

# **Combination of assay results**

Purpose: from n valid assay results to one result

### Are estimates derived from **independent assays**?

Execution of either <u>does not affect</u> the probabilities of the possible outcomes of the other e.g. different runs, different days, different working solutions, ...

Assays on successive days using the original and retained dilutions of the standard are not independent assays.

Combination approach differs for **independent** and **not independent** assays

### **Ph. Eur. Chapter 5.3** Statistical analysis of results of biological assays and tests

1. introduction

- 2. randomisation and independence of individual treatments
- 3. assays depending upon quantitative responses
  - 3.2. the parallel-line model
  - 3.3. the slope-ratio model
  - 3.4. extended sigmoid dose-response curves
- 4. assays depending upon quantal responses
  - 4.2. the probit method
  - 4.3. the logit method
  - 4.5. the median effective dose
- 5. examples

6. combination of assay results

6.2. combination of independent assay results


6.3. unweighted combination of assay results

7. beyond this annex

- 8. tables and generating procedures
- 9. glossary of symbols
- 10. literature




# Three types of combination of assay results



Homogeneity of assay results, p-value: 0.298

Geometric	Potency (1000 IU/mg)			
combination	Estimate	(LCL, UCL)		
Weighted	938.014	(912.564, 964.174)		
Semi-weighted	938.014	(912.465, 964.279)		
Unweighted	943.314	(884.424, 1006.12)		
DEN( comfidence	1			

95% confidence limits are reported.






The assay can be considered homogeneous if the variance between the individual estimates is not greater than those predicated by the individual confidence intervals

### Evaluation based on p-value of $\chi^2$ distribution:

- p-value >0.10 => potency estimates sufficiently homogeneous
- p-value  $\leq 0.10 =>$  potency estimates heterogeneous




Homogeneity of assay results, p-value: 0.298


Geometric	Potency (1000 IU/mg)			
combination	Estimate	(LCL, UCL)		
Weighted	938.014	(912.564, 964.174)		
Semi-weighted	938.014	(912.465, 964.279)		
Unweighted	943.314	(884.424, 1006.12)		

95% confidence limits are reported.




# **Weighted combination**





Estimate	(LCL, UCL)	Confidence level	DF
936.639	(874.648, 1003.23)	95 %	25
970.838	(919.331, 1026.05)	95 %	25
923.102	(888.590, 958.767)	95 %	25



	Arithmetic	Potenc	cy (1000 IU/mg)	Rel. To	Estimate (%)
	combination	Estimate	(LCL, UCL)	Estimate	(LCL, UCL)
	Weighted	937.362	(911.560, 963.164)	100	(97.25, 102.75)

The more measurements in individual assays the tighter weighted confidence interval



# **Semi-weighted combination**

 weighted

 combination

 Weighted' Mean  $\pm 2 * \sqrt{\frac{1}{\sum W'}}$ 

Semi-

*W* weight calculated based on intra- and inter-assay variation

 $W' = \frac{1}{intra^2 + inter^2}$ 

$$\frac{\text{intra-assay variation}}{\text{intra}^2 = \frac{1}{W}}$$
same *W* as calculated for weighted combination
$$\frac{\text{inter-assay variation}}{\text{inter}^2 = \frac{\sum (M - \overline{M})^2}{1 - \sum \text{intra}^2} - \frac{\sum \text{intra}^2}{1 - \sum \text{intra}^2}$$

n number of assays M assay estimate  $\overline{M}$  mean of estimates

n-1

 $\boldsymbol{n}$ 

Estimate	(LCL, UCL)	Confidence level	DF
774.169	(750.584, 798.498)	95 %	inf
737.265	(714.811, 760.428)	95 %	inf
817.927	(793.001, 843.639)	95 %	inf

# Intra- and inter-assay variation

### Enlarged confidence interval

Homogeneity of assay results, p-value: < 0.001


Arithmetic	Uni	ts (ug/ED50)	Rel. To	Estimate (%)		
combination	Estimate	(LCL, UCL)	Estimate	(LCL, UCL)		
Weighted	773.656	(759.822, 787.491)	100	(98.21, 101.79)		
Semi-weighted	776.194	(729.570, 822.818)	100	(93.99, 106.01)		
Unweighted	776.454	(676.146, 876.761)	100	(87.08, 112.92)		

95% confidence limits are reported.

Unweighted RSD(%): 5.2



# **Unweighted combination**



Critical values of the t-distribution p = 0.05p = 0.01df p = 0.05df p = 0.011 12.706 63.656 22 2.0742.819 4.303 2 9.925 24 2.064 2.797 3 3.182 5.841 26 2.056 2.7794 2.7764.604 28 2.048 2.763 5 2.5714.032 30 2.0422.7506 2.4473.707 35 2.030 2.7247 3.499 2.365 40 2.021 2.7048 2.306 3.355 45 2.014 2.6909 3.250 2.678 2.262 50 2.009 10 2.228 3.169 60 2.000 2.6602.1793.055 70 1.994 2.64812 2.145 2.97780 1.990 2.639 14 16 2.1202.92190 1.987 2.632 18 2.101 2.878100 1.984 2.626 00 20 2.086 2.8451.960 2.576


Estimate	(LCL, UCL)	Confidence level	DF
936.639	(874.648, 1003.23)	95 %	25
970.838	(919.331, 1026.05)	95 %	25
923.102	(888.590, 958.767)	95 %	25

### n is usually low Large confidence interval

Arithmetic	Poten	cy (1000 IU/mg)	Rel. To	Estimate (%)
combination	Estimate	(LCL, UCL)	Estimate	(LCL, UCL)
Weighted	937.362	(911.560, 963.164)	100	(97.25, 102.75)
Semi-weighted	937.362	(911.458, 963.266)	100	(97.24, 102.76)
Unweighted	943.526	(882.411, 1004.64)	100	(93.52, 106.48)



## Three types of combination of assay results



apean Directionale Direction européenne for the Quality de la qualité of Medicines du médicanent Albeithé au Seina de ganté

# Combine assays in CombiStats online

### Select the assays in a folder

### Combine assay results

European Directorate | Direction européenn for the Quality de la qualité of Medicines du médicament & HealthCare & soins de sant

My workspace / I	My folder			New name
+ New folder	+ New record → 🗲 Up View →	Combine	<b>Condition for combination</b> :	Erythromycin_combined
🗆 Туре	Name	Export to zip file	<section-header><section-header><list-item><list-item><list-item><text></text></list-item></list-item></list-item></section-header></section-header>	🕀 💼 David
	4PL with log transformation A114 PhEur Ex 541 4PL Sigmoid	Move to	assay must be published	🕀 💼 Elena
	A302 Erythromycin Assay 1 PLA Blocks	â Delete		
	A303 Erythromycin Assay 2 PLA Blocks			
	A304 Erythromycin Assay 3 PLA Blocks		<ul> <li>analysis results should be present</li> <li>assay must be published</li> </ul> For sigmoid curve models potency estimates or effective doses can be combined Image: Combine Cose all state Combine Cose all state and ERTHROMYCIN ASSAY 3 PLA BLOCKS × Conductive Address of a state and environment of the state an	Combined
	A323 Yellow Fever Vaccine Exponential R	Reg		Potency estimates O Effective dose
				Assays that can be combined:
Or com	bine opened ass	ays		A302 Erythromycin Assay 1 PLA Blocks
🗈 🖆 - 🖻	Publish 👻 🕨 Run 🗐 Report 👻	1 문 🛤 🖬	🖬 🚯 🖍 Raw data - Combine Close all	A303 Erythromycin Assay 2 PLA Blocks
A302 ERYTHRO	MYCIN ASSAY 1 PLA BLOCKS ×	303 ERYTHROMYCIN A	SSAY 2 PLA BLOCKS × 🗎 A304 ERYTHROMYCIN ASSAY 3 PLA BLOCKS ×	A304 Erythromycin Assay 3 PLA Blocks
				Cancel OK
	Council of Europa 2025			council of E

# **Available Options**

https://combistats.edqm.eu/help/ EN17 Combination of Assay Results

#### Combination of assay results

Remark	
I can write	

#### Only fields Remark, Combine by and Confidence level for combination can be **modified**

# The content of Information about assays and Potency results **cannot be modified**

# One or more potency results can be excluded by **double-click**

#### Once the options chosen, run the analysis





#### Information about assays

Entry	Assay name	Project	Assay
1	A302 Erythromycin Assay 1 PLA Blocks	Erythromycin	1
2	A303 Erythromycin Assay 2 PLA Blocks	Erythromycin	2
3	A304 Erythromycin Assay 3 PLA Blocks	Erythromycin	З

#### Potency results

Entry	Preparation	Id.	Potency	Estimate	(LCL, UCL)	Confidence level	DF
1	Sample 1	т	1000 IU / mg	936.639	(874.648, 1003.23)	95 %	25
2	Sample 1	Т	1000 IU / mg	970.838	(919.331, 1026.05)	95 %	25
3	Sample 1	÷	<del>1000 IU / mg</del>	<del>923.102</del>	<del>(888.590, 958.767)</del>	<del>95 %</del>	<del>25</del>

#### Combine by

Preparation	~
Preparation	
14	

### Confidence level

#### 95 Integer between 80 and 99

96

#### 33 © EDQM, Council of Europe, 2025. All rights reserved.

# **Arithmetic and geometric combination**

### **Geometric combination**

#### Potency results

Entry	Preparation	Id.	Potency	Estimate	(LCL, UCL)	Confidence level	DF
1	Sample 1		1000 IU / mg	936.639	(874.648, 1003.23)	95 %	25
2	Sample 1		1000 IU / mg	970.838	(919.331, 1026.05)	95 %	25
3	Sample 1		1000 IU / mg	923.102	(888.590, 958.767)	95 %	25

### CombiStats software

- ✓ applies log-transformation to estimates and confidence limits,
- ✓ performes calculations on the log-scale,
- ✓ appies **anti-log-function** on final results

### Arithmetic combination

### If the estimates are already on the log scale, no transformation prior to the combination

#### Effective dose results

Entry	Preparation	Id.	Units	Estimate	(LCL, UCL)	Confidence level	DF
1	Sample 1	А	log10 ED50/vial	4.73374	(4.45322, 5.01399)	95 %	inf
1	Sample 2	А	log10 ED50/vial	3.59821	(3.31617, 3.87813)	95 %	inf

### CombiStats software

✓ performes calculations on the log-scale

If potency unit contains "**log**", <u>arithmetic combination only</u> is displayed. Otherwise, geometric combination presented by defaults. User has the possibility to change to arithmetic combination



# **Combined results**

#### Combined by Preparation

#### Potency results

Entry	Preparation	Id.	Potency	Estimate	(LCL, UCL)	Confidence level	DF
1	Sample 1	т	1000 IU / mg	936.639	(874.648, 1003.23)	95 %	25
2	Sample 1	Т	1000 IU / mg	970.838	(919.331, 1026.05)	95 %	25
3	Sample 1	U	1000 IU / mg	923.102	(888.590, 958.767)	95 %	25

#### Combine by

Confidence	level

Preparation

onnachee	
95	

#### Preparation Sample 1

Geometric combination

Homogeneity of assay results, p-value: 0.298

%

Geometric	Potency (1000 IU/mg)		Rel. To	Estimate (%)	Rel. To Assumed/Assigned (%)		
combination	Estimate	(LCL, UCL)	Estimate	(LCL, UCL)	Estimate	(LCL, UCL)	
Weighted	938.014	(912.564, 964.174)	100	(97.29, 102.79)	93.80	(91.26, 96.42)	
Semi-weighted	938.014	(912.465, 964.279)	100	(97.28, 102.80)	93.80	(91.25, 96.43)	
Unweighted	943.314	(884.424, 1006.12)	100	(93.76, 106.66)	94.33	(88.44, 100.61)	

95% confidence limits are reported.

Unweighted gCV(%): 2.6

#### Potency **units** should be the same (case sensitive) If potency **values** not the same, no Rel. to Assumed/Assigned (%)

#### Potency results

Entry	Preparation	ld.	Potency	Estimate	(LCL, UCL)	Confidence level	DF
1	Sample 1	Т	1000 IU / mg	936.639	(874.648, 1003.23)	95 %	25
2	Sample 1	Т	1000 IU / mg	970.838	(919.331, 1026.05)	95 %	25
3	Sample 1	Т	? IU / mg	923.102	(888.590, 958.767)	95 %	25

Combine by

#### **Confidence level**

Preparation

 $\sim$ 



Preparation Sample 1

Geometric combination

~

Homogeneity of assay results, p-value: 0.298

Geometric	Pote	ency (IU/mg)	Rel. To Estimate (%)		
combination	Estimate	(LCL, UCL)	Estimate	(LCL, UCL)	
Weighted	938.014	(912.564, 964.174)	100	(97.29, 102.79)	
Semi-weighted	938.014	(912.465, 964.279)	100	(97.28, 102.80)	
Unweighted	943.314	(884.424, 1006.12)	100	(93.76, 106.66)	

95% confidence limits are reported.

Unweighted gCV(%): 2.6







36 © EDQM, Council of Europe, 2025. All rights reserved.

# **Thank you for your attention**



### Stay connected with the EDQM

EDQM Newsletter: https://go.edqm.eu/Newsletter LinkedIn: https://www.linkedin.com/company/edqm/ X: @edqm\_news Facebook: @EDQMCouncilofEurope

